GLP-1semaglutideglp-1cancer riskobesity

Obesity Reviews says GLP-1 agonists do not raise overall cancer risk

The review argues incretin therapy may cut some obesity-related cancers while flagging medullary thyroid carcinoma as a continuing safety question.

By Maren Holt · Senior Reporter, GLP-1

Oct 20 20:00 ETSource: Obesity reviews : an official journal of the International Association for the Study of Obesity

The wire

01The narrative review in Obesity Reviews concludes current data show no increase in overall cancer risk with GLP-1 receptor agonists and possible reductions in some obesity-driven cancers.
02Clinicians fielding cancer-risk questions from patients on semaglutide or tirzepatide get a consolidated read on protective signals alongside the medullary thyroid carcinoma concern.
03It is a review, not new outcome data; the authors note open questions about durability of benefit after weight regain and stress pairing drugs with lifestyle measures to preserve muscle.

From the source

GLP-1 Receptor Agonists and Cancer Risk in Obesity Treatment
Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026 Oct 21 · Hofseth LJ, Murphy EA, Playdon MC et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42906947/